新科学想法 › 文献管理 › 浏览文献

Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas

super1129 添加于 2011-12-18 18:29 | 1179 次阅读 | 0 个评论

作者
Mucke HAM
摘要
In the field of nonpeptide NCEs with endothelin receptor antagonist activity, a burst in corporate IP filings occurred in the 1990s once the human endothelin system had been characterized, but patent activity has declined in the past decade. Universities have not been active in this area of research to a degree that would have led to many patent applications. While three endothelin receptor antagonists (bosentan, sitaxentan and ambrisentan) are already available for the treatment of pulmonary arterial hypertension, the use of such compounds for the larger therapy areas of heart failure, cancer and nephropathy is still being evaluated in late-stage clinical trials. Marketed and advanced-stage endothelin receptor blockers have remarkably little chemical diversity; thus, the substantially larger chemical space defined by patenting remains to be explored.
详细资料
- 文献种类:期刊
- 期刊名称: IDrugs : the Investigational Drugs Journal
- 期刊缩写: IDrugs
- 期卷页: 2009年第12卷第6期 366-375页
- 地址: HM Pharma Consultancy, Wien, Austria. h.mucke@hmpharmacon.com
- ISBN: 1369-7056
- 备注:PMID:19517317
相关链接 URL
附件
Small-molecule endothelin receptor antagonists: a review of patenting activity a
super1129 的文献笔记订阅